{"id":"mycophenolate-mofeti","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain)"},{"rate":"20-30","effect":"Leukopenia"},{"rate":"10-20","effect":"Anemia"},{"rate":"15-25","effect":"Infection"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Tremor"}]},"_chembl":null,"patents":[],"_fixedAt":"2026-03-30T18:22:18.273882","_dailymed":{"setId":"127eabe2-8386-452a-ad6b-d879e1f2c099","title":"MYCOPHENOLATE MOFETIL POWDER, FOR SUSPENSION [NORTHSTAR RX LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mycophenolate mofetil is a prodrug that is rapidly hydrolyzed to mycophenolic acid (MPA), which preferentially inhibits IMPDH type II, the predominant form in activated lymphocytes. This leads to depletion of guanosine nucleotides required for DNA synthesis, causing selective antiproliferative effects on T and B cells while sparing other cell types. It is used as an immunosuppressant to prevent organ rejection and treat autoimmune conditions.","oneSentence":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:17:47.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients"},{"name":"Active lupus nephritis"},{"name":"Autoimmune conditions requiring immunosuppression"}]},"_fixedFields":["generics(24)","patents(0)"],"patentStatus":"Off-patent — no active Orange Book patents","trialDetails":[{"nctId":"NCT05436418","phase":"PHASE1, PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":"Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation","enrollment":260},{"nctId":"NCT00301600","phase":"NA","title":"Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy","status":"COMPLETED","sponsor":"Nanjing University School of Medicine","startDate":"2003-01","conditions":"IGA Nephropathy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE MYELOID LEUKAEMIA"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"CLOSTRIDIAL INFECTION"},{"count":1,"reaction":"DISEASE RECURRENCE"},{"count":1,"reaction":"DRUG CLEARANCE DECREASED"},{"count":1,"reaction":"DRUG INTERACTION"},{"count":1,"reaction":"GENERAL PHYSICAL HEALTH DETERIORATION"},{"count":1,"reaction":"HAEMOPHILUS INFECTION"},{"count":1,"reaction":"MYCOBACTERIAL INFECTION"},{"count":1,"reaction":"THERAPY NON-RESPONDER"}],"_patentsChecked":true,"_approvalHistory":[],"publicationCount":3,"genericManufacturers":24,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Alkem Labs Ltd","Amneal","Apotex","Apotex Corp","Aurobindo Pharma","Aurobindo Pharma Ltd","Concord Biotech Ltd","Dr Reddys Labs Ltd","Hetero Labs Ltd V","Hikma","Jubilant Cadista","Lannett Co Inc","Mylan","Rising","Sandoz","Strides Pharma","Strides Pharma Intl","Teva Pharms","Teva Pharms Usa","Vistapharm Llc","Wuxi","Zhejiang Hisun Pharm","Zydus Pharms Usa Inc"],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Mycophenolate Mofeti","genericName":"Mycophenolate Mofeti","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing proliferation of T and B lymphocytes. Used for Prevention of organ rejection in renal, cardiac, and hepatic transplant recipients, Active lupus nephritis, Autoimmune conditions requiring immunosuppression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}